Gastric Cancer Stage II, Gastric Cancer Stage III, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Conditions
Keywords
Oncoxin, Nutritional supplement, Chemotherapy, Oxidative stress, Antioxidant
Brief summary
It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. Food supplement ONCOXIN (ONCX) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. Present study is a real world experience study intended to evaluate the efficacy of ONCX in cancer patients.
Detailed description
The study was conducted at 9 centers across the Russia and Kazakhstan. Patients were allocated in 2:1 comparison groups for the ONCX and control groups, respectively. A total of 133 patients were enrolled in the study; 84 in the ONCX group and 49 as controls. ONCX contains microelements, vitamins, amino acids and certain naturally occurring, biologically active substances. It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain the Quality of life in cancer patients.
Interventions
DIETARY_SUPPLEMENTONCOXIN®
Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
Sponsors
Catalysis SL
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Study multicenter open-label nonrandomized clinical trial in two parallel groups with a 20-day treatment period. No follow-up period was intended. Following visits were scheduled: Visit 1 - the first day of 2nd and further course of ACT before ACT drugs administration; Visit 2 - 7±1 days before next course of ACT; Visit 3 - the day of next course of ACT before ACT drugs administration (21±3 days after Visit 1). It is expected, that the proportion of patients with MCID improvement in total SDS ESAS was 50% in ONCX group and 20% in control group (with baseline total SDS ESAS of 30 points). Based on patients' allocation as 2:1 in comparison groups for the ONCX and control groups, respectively, alpha 0.05 and power not less than 0.9 data of 120 patients has to be analyzed. With the dropout of 25% 150 patients has to be included in the study (100 ONCX/50 controls).
Eligibility
Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female patients who had signed an informed consent. 2. Males and females aged 50-70 y/o 3. Gastric cancer IIB-IIIC, Non-small cell lung cancer IIB-IIIA 4. R0 surgery 5. Adjuvant chemotherapy (ACT) required, 2nd and further course of ACT, XELOX regimen of ACT for gastric cancer and paclitaxel+carboplatin regimen for non-small cell lung cancer. 6. Body mass index (BMI) ≥ 15, serum albumin ≥ 25 g/l. 7. Eastern Cooperative Oncology Group performance status ≤ 2
Exclusion criteria
1. Severe concomitant diseases or conditions that may complicate or make impossible the patient's participation in the study, or make it difficult to interpret the clinical data (including mental disorders, severe infectious and parasitic diseases and intolerability to any of the ONCX components). 2. The patient's family or official relations with a member of staff of the study center. 3. The patient's failure to assess his/her physical and/or emotional condition. 4. The patient's failure to comply with the study requirements. 5. The patient's refusal to participate in the study and pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life improvement | 20 days | The proportion of patients who had an improvement in the QoL corresponding to the minimal clinically important difference (MCID) that any patient was able to feel at Visits 2 in total SDS ESAS (6 points within patient change for improvement) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Emotional Quality of life | 20 days | emotional SDS ESAS domains |
| Toxicity produced by Chemotherapy | 20 days | Common toxicity criteria NCI-CTC. Common Terminology Criteria for Adverse Events (AE) is a descriptive terminology which can be utilized for Adverse Event reporting. A grading (severity) scale is provided for each AE term. |
| Physical Quality of Life | 20 days | Physical SDS ESAS scores |
| Nutritional level | 20 days | Serum albumin level measures |
Countries
Kazakhstan, Russia
Outcome results
None listed